Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the impact of the phase 3 PALOMA-2 trial (NCT01740427) in estrogen receptor (ER)–positive/HER2-negative advanced breast cancer.

The trial compared letrozole (Femara) in combination with palbociclib (Ibrance) vs letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative advanced breast cancer, Goetz explains.

Additional trials in the first-line setting, such as the phase 3 monarchE (NCT03155997) and MONALEESA-2 (NCT01958021) trials, tested different CDK4/6 inhibitors in combination with endocrine therapy, Goetz continues. The trials confirmed a benefit in progression-free survival with the addition of a CDK4/6 inhibitor to treatment, and as data have matured, investigators are beginning to gather overall survival data, Goetz concludes.